Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

Abbott gets green light to challenge diabetes patents
Pharma
Dispute hinges on clauses set out in decade-old settlement and licensing agreement | Federal Circuit unpersuaded by arguments suggesting that a federal court erred in denying a preliminary injunction.   4 January 2024
Emcure prevails against ‘fairytale’ accusations
Biotech
Emcure fends off COVID-19 trade secrets suit in Washington | A US biotech had inked a short-lived deal with Indian generic pharma company’s subsidiary.   5 December 2023
Daiichi Sankyo secures nearly $46m legal fees in antibody arbitration
Generics
Final award follows and incorporates the August 2022 decision by the arbitrator denying all claims levied at the Japanese company | Dispute involves antibody drug conjugate technology.   30 November 2023
Europe
Is the court’s public access rule unfit for purpose? Lawyers at Mathys & Squire are arguing for pleadings and evidence to be automatically made available on request, finds Muireann Bolger.   28 November 2023
Pharma
Big pharma company relies on procedural arguments to fend off a complaint alleging that it engaged in excessive pricing | Feud centres on one of the most successful blockbuster drugs of all time.   16 November 2023
Americas
Controversial rule precludes a patent review if there is parallel litigation | Big pharma and tech companies insist the rule is “arbitrary and capricious” | US agency backs Vidal’s authority, calling a proposed intervention “unnecessary”.   14 November 2023
Pharma
Commission targets big pharma companies over ‘improper listings’ | Agency argues that alleged inaccuracies may delay lower-cost generic drug competition, stall drug development, and stifle innovation.   9 November 2023
Americas
Appeals court faults lower court’s claim construction and its reliance on intrinsic evidence alone | Court emphasises that extrinsic evidence is needed in litigation over heart disease drug.   7 November 2023
MedTech
Precedential ruling finds errors in lower court’s findings in a case concerning medical devices | Earlier verdict has been vacated and remanded.   2 November 2023
Pharma
Gene-sequencing giant to be punished for defying EC authority by acquiring cancer treatment firm say FT sources | EC concerns over anti-competitive effects could scupper controversial deal.   10 October 2023

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.